文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

浓度-时间曲线下面积阈值用于个体化多黏菌素B给药:预测疗效与肾毒性

An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria.
PubMed 文献 · Crit Care · 2022-10-18
一句话结论重症患者多黏菌素B的AUCss,24h维持在50-100 mg·h/L与降低肾毒性并保证临床疗效相关,推荐进行治疗药物监测以个体化给药。

该真实世界队列纳入393例碳青霉烯类耐药革兰阴性菌感染患者,用经验证的贝叶斯法从两份血样估算稳态24小时浓度-时间曲线下面积(AUCss,24h),通过分类回归树分析推导影响多黏菌素B相关肾毒性和临床反应的AUCss,24h阈值,并用Cox回归和逻辑回归验证。结果肾毒性AUCss,24h阈值为>99.4 mg·h/L、临床反应阈值为>45.7 mg·h/L;AUCss,24h>100 mg·h/L是急性肾损伤的显著预测因子(HR 16.29,95%CI 8.16-30.25,P<0.001),AUCss,24h≥50 mg·h/L与临床反应独立相关(OR 4.39,95%CI 2.56-7.47,P<0.001),但上述暴露与死亡率无关。结论认为AUCss,24h 50-100 mg·h/L与降低肾毒性同时保证临床疗效相关,推荐进行治疗药物监测以个体化多黏菌素B给药。

要点

  • 碳青霉烯类耐药革兰阴性菌感染患者中,AUCss,24h>100 mg·h/L是急性肾损伤的显著预测因子(HR 16.29,95%CI 8.16-30.25,P<0.001)。
  • AUCss,24h≥50 mg·h/L与临床反应独立相关(OR 4.39,95%CI 2.56-7.47,P<0.001)。
  • 分类回归树分析推导的肾毒性阈值为AUCss,24h>99.4 mg·h/L,临床反应阈值为>45.7 mg·h/L。
  • AUCss,24h 50-100 mg·h/L与降低肾毒性同时保证临床疗效相关,但暴露与死亡率无关。
  • 谷浓度1.2-2.8 mg/L与结局的相关性类似AUCss,24h;推荐进行治疗药物监测以个体化多黏菌素B给药。

适用人群与场景

  • 碳青霉烯类耐药革兰阴性菌感染的重症患者,真实世界队列共393例。

诊断标准与关键阈值

  • 肾毒性(急性肾损伤)的AUCss,24h阈值为>99.4 mg·h/L(分类回归树分析推导)。
  • 临床反应的AUCss,24h阈值为>45.7 mg·h/L(分类回归树分析推导)。
  • Cox回归中AUCss,24h>100 mg·h/L为急性肾损伤的预测阈值;逻辑回归中AUCss,24h≥50 mg·h/L为临床反应的相关阈值。

处置流程与药物剂量

  • 用经验证的贝叶斯法从两份血样估算AUCss,24h。
  • AUCss,24h目标区间为50-100 mg·h/L,与降低肾毒性同时保证临床疗效相关。
  • 推荐进行治疗药物监测以个体化多黏菌素B给药。

研究设计与关键结果

  • 真实世界队列研究纳入393例患者,急性肾损伤发生率29.0%,临床反应率63.4%,30天全因死亡率35.4%。
  • 分类回归树分析推导肾毒性AUCss,24h阈值>99.4 mg·h/L、临床反应阈值>45.7 mg·h/L。
  • Cox回归显示AUCss,24h>100 mg·h/L是急性肾损伤的显著预测因子(HR 16.29,95%CI 8.16-30.25,P<0.001)。
  • 逻辑回归显示AUCss,24h≥50 mg·h/L与临床反应独立相关(OR 4.39,95%CI 2.56-7.47,P<0.001)。
  • 上述暴露与死亡率无关;谷浓度1.2-2.8 mg/L与结局的相关性类似AUCss,24h。

证据类型、等级与局限

  • 证据类型:真实世界队列研究;采用经验证贝叶斯法估算AUCss,24h,分类回归树分析推导阈值,Cox回归和逻辑回归验证。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对碳青霉烯类耐药革兰阴性菌感染的重症患者,可将AUCss,24h 50-100 mg·h/L作为平衡疗效与肾毒性的目标区间。
  • AUCss,24h>100 mg·h/L与急性肾损伤风险显著升高相关(HR 16.29,95%CI 8.16-30.25,P<0.001),需据此调整给药。
  • AUCss,24h≥50 mg·h/L与临床反应独立相关(OR 4.39,95%CI 2.56-7.47,P<0.001),低于此阈值可能疗效不足。
  • 推荐进行治疗药物监测以个体化多黏菌素B给药。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Evidence supports therapeutic drug monitoring of polymyxin B, but clinical data for establishing an area under the concentration-time curve across 24 h at steady state (AUCss,24 h) threshold are still limited. This study aimed to examine exposure-response/toxicity relationship for polymyxin B to establish an AUCss,24 h threshold in a real-world cohort of patients.

METHODS: Using a validated Bayesian approach to estimate AUCss,24 h from two samples, AUCss,24 h threshold that impacted the risk of polymyxin B-related nephrotoxicity and clinical response were derived by classification and regression tree (CART) analysis and validated by Cox regression analysis and logical regression analysis.

RESULTS: A total of 393 patients were included; acute kidney injury (AKI) was 29.0%, clinical response was 63.4%, and 30-day all-cause mortality was 35.4%. AUCss,24 h thresholds for AKI of > 99.4 mg h/L and clinical response of > 45.7 mg h/L were derived by CART analysis. Cox and logical regression analyses showed that AUCss,24 h of > 100 mg h/L was a significant predictor of AKI (HR 16.29, 95% CI 8.16-30.25, P < 0.001) and AUCss,24 h of ≥ 50 mg h/L (OR 4.39, 95% CI 2.56-7.47, P < 0.001) was independently associated with clinical response. However, these exposures were not associated with mortality. In addition, the correlation between trough concentration (1.2-2.8 mg/L) with outcomes was similar to AUCss,24 h.

CONCLUSIONS: For critically ill patients, AUCss,24 h threshold of 50-100 mg h/L was associated with decreased nephrotoxicity while assuring clinical efficacy. Therapeutic drug monitoring is recommended for individualizing polymyxin B dosing.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Yang J, Liu S, Lu J, et al. An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria. Crit Care. 2022. PMID: 36258197. doi:10.1186/s13054-022-04195-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。